Donna Reuter
Overview
Leveraging her experiences as a practitioner in the healthcare industry, Donna capably serves clients with her industry experience and her commitment to achieving client goals.
Career & Education
- Mitchell Hamline School of Law, J.D., 2019
- University of Minnesota, Pharm.D., 2011
- California State University, Fresno, B.A., Mass Communication and Journalism, 2006
- Minnesota
- District of Columbia
- U.S. District Court for the District of Minnesota
- U.S. Court of Appeals for the Eighth Circuit
Donna's Insights
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies.
Client Alert | 5 min read | 04.07.26
Weight-Loss Drug Coverage Obligations: A Litigation and Regulatory Update
Client Alert | 3 min read | 02.24.26
DOJ v. OhioHealth Confirms Antitrust Enforcers’ Continued Focus on Health Care Markets
Client Alert | 5 min read | 02.20.26
Trump Administration Pursues MFN Pricing for Prescription Drugs
Insights
- |
07.01.24
Crowell & Moring’s Health Law Blog
Practices
Donna's Insights
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies.
Client Alert | 5 min read | 04.07.26
Weight-Loss Drug Coverage Obligations: A Litigation and Regulatory Update
Client Alert | 3 min read | 02.24.26
DOJ v. OhioHealth Confirms Antitrust Enforcers’ Continued Focus on Health Care Markets
Client Alert | 5 min read | 02.20.26
Trump Administration Pursues MFN Pricing for Prescription Drugs
